Research programme: anti-infectives - PanThera Biopharma

Drug Profile

Research programme: anti-infectives - PanThera Biopharma

Alternative Names: Anthrax therapies - PanThera Biopharma; Botulinum toxin therapies - PanThera Biopharma; α-Arylamino hydroxamic acids as anthrax lethal factor inhibitors - PanThera Biopharma

Latest Information Update: 11 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hawaii Biotech
  • Developer PanThera Biopharma; University of Hawaii
  • Class Antitoxins; Small molecules
  • Mechanism of Action Anthrax toxin inhibitors; Botulinum toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anthrax; Botulism; Dengue; West Nile virus infections

Most Recent Events

  • 05 Mar 2014 Hawaii Biotech receives contract from the Defense Threat Reduction Agency for the development of drugs for Botulism
  • 04 Feb 2014 Hawaii Biotech receives grant from National Institute of Allergy and Infectious Diseases for anti-toxin development in Anthrax
  • 26 Mar 2009 Preclinical development is ongoing for Anthrax in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top